Eli Lilly scoops up Houston biotech startup in $300 million deal

big pharma deal

CrossBridge Bio co-founder and CEO Michael Torres. Photo via LinkedIn

Pharmaceutical giant Eli Lilly has acquired Houston biotech startup CrossBridge Bio, which develops antibody-drug conjugates for cancer, in a deal worth up to $300 million. The deal was celebrated by TMC Venture Fund and the University of Texas Health Science Center at Houston last week.

CrossBridge, founded in 2023, is developing ADCs based on research by Kyoji Tsuchikama and Zhiqiang An, both of UT Health Houston. Tsuchikama is an associate professor of medicinal chemistry and a globally recognized ADC pioneer, and An is a professor of molecular science and vice president of drug discovery.

Antibody-drug conjugates (ADCs) are a potent combination of targeted therapy and chemotherapy that kills cancer cells while saving healthy tissue.

Clinical trials for CrossBridge’s primary ADC candidate, CBB-120, are expected to start this year, pending approval from the U.S. Food and Drug Administration (FDA).

“I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding,” Michael Torres, co-founder and CEO of CrossBridge, said in a news release. “By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach.”

Under the Lilly deal, CrossBridge shareholders were expected to receive an upfront payment along with a follow-up payment based on the achievement of certain milestones.

In 2024, CrossBridge closed a $10 million seed round. Among the investors in CrossBridge are the Texas Medical Center Venture Fund, CE-Ventures, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and the Cancer Prevention and Research Institute of Texas (CPRIT). It was formed in TMC Innovation’s Accelerator for Cancer Therapeutics program."Built within the TMC ecosystem, CrossBridge Bio grew with the support, funding, and resources that helped shape its trajectory. TMC led the company's early financing and watched it evolve from its earliest days to its acquisition by Eli Lilly," William McKeon, president and CEO of the Texas Medical Center, shared in a LinkedIn post. "[This is a] strong reminder that breakthrough science and the right early backing can change what’s possible."

From Your Site Articles

This week's roundup of Houston innovators includes Michael Torres of CrossBridge Bio, Aileen Allen of Mercury, and Ryan Reisner of SeekerPitch. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes three innovators across therapeutics, venture capital, and HR software.

Michael Torres, CEO of CrossBridge Bio

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and CE-Ventures. Photo via crossbridgebio.com

A Houston biotech company based off research out of UTHealth Houston has raised seed funding to continue developing its cancer-fighting therapeutic.

CrossBri dge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and Crescent Enterprises' VC arm, CE-Ventures. The round also included participation from Portal Innovations, Alexandria Venture Investments, Linden Lake Labs, and several pre-seed investors.

“We are thrilled to have the support of such experienced investors who share our vision of bringing transformative cancer therapies to patients in need,” Michael Torres, CEO of CrossBridge Bio, says in a news release. Torres served as an entrepreneur in residence of ACT. Continue reading.

Aileen Allen, venture partner at Mercury

Aileen Allen joined Mercury as venture partner and is on the board of the Houston Angel Network. Photo courtesy of Mercury

When Aileen Allen was contemplating a big career move — swapping sides of the table from tech company to venture investor — she was motivated by driving gender and experience diversity amongst decision makers.

"I've worked for VC-backed companies for most of my career and had the opportunity as an executive to be in the boardroom during that time," she says on the Houston Innovators Podcast. "One of my takeaways was that very few of my board members looked like me. I had one or two women on any of my boards at a time in totality, and very few of my board members had been operators."

"I'd really like to change that, and I'd like there to be better representation and diversification in the boardroom," she adds. Continue reading.

Ryan Reisner, president and founder of SeekerPitch

Ryan Reisner is the\u00a0president and founder of SeekerPitch and The Reisner Group. Photo via LinkedIn

Confident job seekers have mostly been of the mindset that if they can just get in front of an employer, they can sell themselves into an offer for the open position. The obstacle then, is getting through the screening process to get an actual interview.

Until recently, the price of admission for starting or progressing in a desired career was a resume and cover letter stellar enough to catch the eye of the human resources and recruiting team. Outside of being buried in the immense pile of resumes recruiters do not have the bandwidth to get to, standing out in the sea of candidates can be daunting.

Resumes do not tell the full story as it is and it’s almost impossible for applicants to put their potential, soft skills and work personality into a document to be reviewed. So, what’s the solution?

It is a multi-layered problem, which requires a multi-layered solution, but one of the options gaining steam in the recruitment space is provided by SeekerPitch, a Houston-based HR technology platform utilizing generative AI to make hiring and interviewing more efficient.

“I've noticed that there's a ton of people that slip through the cracks,” says Ryan Reisner, president and founder of SeekerPitch and The Reisner Group. “And we spend all our time interviewing people to see if they have the soft skills. Resumes are hard skills. And now with AI, anybody can build the same exact resume. Everybody can say they have communication skills, leadership skills, and a lot of people say they have those." Continue reading.

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and CE-Ventures. Photo via Getty Images

Houston biotech startup secures $10M seed round to propel cancer-fighting therapy from bench to bedside

fresh funding

A Houston biotech company based off research out of UTHealth Houston has raised seed funding to continue developing its cancer-fighting therapeutic.

The company is working on the next-generation of antibody-drug conjugates (ADC) therapeutics that process dual payloads as targeted treatments for a set of challenging cancers. The innovative treatment is based on research from UTHealth experts Dr. Kyoji Tsuchikama and Dr. Zhiqiang An.

“Our dual-payload ADC technology is designed to deliver synergistic therapeutic effects using highly stable linkers that ensure payload release only within the targeted cancer cells, thereby maximizing their therapeutic effectiveness while minimizing the liabilities associated with uptake in unintended tissues, as seen with many of today’s cancer treatments," Torres continues.

He explains that the funding will toward advancing CrossBridge's first development candidate, CBB-120, into preclinical non-GLP toxicology studies in addition to derisking the company’s proprietary linker technology with dual-payload applications, per the release.

As a result of the raise, William McKeon, president and CEO of the Texas Medical Center, and Damir Illich, manager of life sciences of CE-Ventures, will join CrossBridge Bio’s board of directors.

“We are proud to back CrossBridge Bio in their mission to develop the next generation of cancer therapies,” McKeon says in the release. “Their dual-payload ADCs are designed to deliver targeted drug release within cancer cells with greater stability, precision, and control. These breakthrough advancements have the potential to change patients’ lives worldwide and we look forward to helping drive their development.”

The Texas Medical Center's ACT program is making sure the most-promising cancer research makes it to its life-saving commercialization stage. Photo via tmc.edu

Houston program buoys promising cancer research with live-saving innovation

act-ing now

How do you bring promising cancer research to the masses? TMC Innovation's Accelerator for Cancer Therapeutics was established with that question in mind.

Funded by a $5 million grant from CPRIT, or the Cancer Prevention and Research Institute of Texas, in 2019 and in collaboration with the Gulf Coast Consortia and the University of Texas Medical Branch, the first cohort began their intensive work in 2021. The deadline to join the next cohort is October 13.

Since its inception, ACT has seen the forming of 19 companies — two of which have been awarded CPRIT seed grants, along with four in contention for one this year — as well as $92 million in dilutive funding and $10 million in non-dilutive funding.

“We’ve recruited investigators and companies from the breadth and width of the state of Texas, so all the way from Lubbock to Galveston from Dallas to the Rio Grande Valley,” Ahmed AlRawi, program manager, tells InnovationMap. “We've had an amazing set of investigators who have gone through the program — 56 teams to be precise.”

AlRawi says that the first pillar of the program is education. To that end, the cohort works with entrepreneurs in residence like Michael Torres. Best known as the co-founder of ReCode Therapeutics, Torres says that one of his greatest passions lies in translating science into medicines. ReCode is a genetic medicines company that is currently clinical-stage. It’s raised more than $300 million in the last two years, certainly something to which scientist-entrepreneurs earlier in their careers would aspire.

A longtime resident of Dallas, Torres moved his family to Houston last year, calling it “the place to be for cancer startups in Texas.”

Initially, says Torres, Houston wasn’t on his radar. But thanks to a call from ACT external advisor Dan Hargrove, Torres realized that the city might be a fit for him and his goals.

“I wanted to find a project that I could help support, sort of take my experience as a cofounder and help guide the next great startup within the ecosystem,” he says.

Torres and AlRawi agree that the biggest successes to come out of ACT so far include March Biosciences, a company from the first cohort, which is focused on developing CAR-T cell strategies to help combat hematological cancers; CPRIT fundee, OmniNano Pharmaceuticals, which uses patented nanotechnology to co-deliver a pair of therapeutical agents to solid tumors; and the latest, CrossBridge Bio.

Part of the most recent cohort, Torres has joined Drs. Kyoji Tsuchikama and Zhiqiang An as the last company’s CEO. To that end, he’s partnered with the world-class researchers out of UT Health Houston to build a next-generation antibody drug conjugate company that he believes will produce “better and safer and more effective drugs than what's currently on the market today.”

All the more reason that Torres he’s glad to have moved to Houston at what he calls “a really exciting time.” He’s thankful for the Texas Medical Center and the relationships it fosters. “We're all sort of aligning on creating a sustainable biotech ecosystem,” he says. And the next big cancer fighting company may well emerge from ACT.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

10+ can't-miss Houston business and innovation events for August

where to be

School is back in session this month, and a busy slate of Houston business and innovation events follows. This month brings demo days, loads of networking opportunities and a major health symposium. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.

Aug. 4 — CEOs: Build With AI, Exit With a Premium

Join Blue People for this engaging presentation by David Lopez, founder of Summa, at the latest installment of Tech + Tequila Talk. Lopez will discuss AI moves that can multiply a company's value.

This event is Tuesday, Aug. 4, from 5-7 p.m. at the Ion. Register here.

Aug. 4 — SEIP Demo Day

The Rice Center for Engineering Leadership will showcase the groundbreaking projects developed by its Summer Engineering Innovation Program at the 2026 Demo Day. Attendees can meet the SEIP participants and partners and hear the teams' final presentations.

This event is Tuesday, Aug. 4, from 6-8 p.m. at the Ion. Register here.

Aug. 5 — Summer Venture Studio Preview Day

The Liu Idea Lab for Innovation and Entrepreneurship (Lilie) will present its inaugural Summer Venture Studio Preview Day this month. Hear from the student founders selected for Lilie's summer cohort, which features teams ranging from the healthcare and artificial intelligence to advanced manufacturing sectors.

This event is Wednesday, Aug. 5, from 4-6 p.m. at the Ion. Register here.

Aug. 11 — Mercury Fund Day at the Ion: How Legacy Software Giants Are Going AI-First

Don’t miss the latest installment of Mercury Fund Day at the Ion, previously known as Software Day. The recurring monthly event features office hours (by application), a keynote and networking opportunities. This month's topic will feature a working conversation with Senior Director of Growth at Twilio Mustafa Ali, Senior Director of Consumer Product at WhatsApp Zafir Khan, and Founder and CEO of utilITise Salim Gheewalla.

This event is Tuesday, Aug. 11, from 3:30-7 p.m. at the Ion. Register here.

Aug. 13 — Pints and Prototypes

TMC Innovation Lab will host its Pints & Prototypes networking event this month. Minneapolis-based Medtronic will support this month's event and has invited guest speakers to share their journey in the medtech scene.

This event is Thursday, Aug. 13, from 4-5:30 p.m. at TMC Innovation Factory. Find more information here.

Aug. 14 — Houston Methodist Cancer Symposium

The 14th Annual Houston Methodist Cancer Symposium will bring together Houston Methodist scientists and physicians from a broad spectrum of fields to discuss everything from innovative translational science to clinical updates. The symposium aims to provide education focused on improving patient care, research collaboration and leading medicine.

This event is Friday, Aug. 14, from 7:30 a.m.-4:45 p.m. at Houston Methodist Research Institute. Find more information and register here.

Aug. 14 — Hands-On Workshop: Build Your Own Reusable AI System

Impact Hub Houston and Social Media Breakfast of Houston will host this hands-on workshop on using Smart Card to create a repeatable process users can hand off to AI. Attendees should bring a laptop, an AI tool, and a task that AI could help with. The workshop will focus on working with ChatGPT, Claude or Gemini.

This event is Friday, Aug. 14, from 8:30-10:30 a.m. at the Ion. Register here.

Aug. 17-21 — Foundations of Cancer Therapeutics Crash Course

The Gulf Coast Consortia will host a virtual course focused on the commercialization aspects of moving cancer therapeutics toward the market. Presenters represent The University of Texas Medical Branch Galveston, the Greater Houston Partnership, TMC Innovation, the University of Houston, Texas Southern University and other major institutions.

This event begins Monday, Aug. 17, at 10 a.m. Register here.

Aug. 20 — Pickle Lab’s Two-Year Anniversary Celebration

Enjoy an evening of open-play pickleball, beats by a live DJ, giveaways and more at the second anniversary celebration of Pickle Lab in the Ion District. Enjoy a free beverage from Second Draught and food for purchase from the Crunchy’s for the Munchies food truck.

This event takes place Thursday, Aug. 20, from 6-9 p.m. at Pickle Lab at the Ion. Register here.

Aug. 20 — SBA Lender Matchmaking Event

Business owners can meet with multiple lenders in scheduled, one-on-one 15-minute sessions during this speed-dating style SBA event. SBA Houston District Office representatives will also be onsite to provide free business advising.

This event takes place Thursday, Aug. 20, from 8:30 a.m.–noon at SBDC Sam Houston State University – The Woodlands Center. Register here.

Aug. 27 — BiteLabs Digital Health and Innovation Summit

TMC Innovation and BiteLabs will host the Digital Health and Innovation Summit, which aims to connect clinicians, founders and investors. The event will include an AI in biotech panel, a healthcare AI ethics panel, a hiring in digital health panel, and pitches from BiteLabs USA HealthTech, AI, and Innovation Fellowship.

This event takes place Thursday, Aug. 27, from 10 a.m.–5 p.m. at TMC Innovation Factory. Register here.

Houston nonprofit wins Meta grant to study AI glasses for disabilities

Helping Houston

A grant from Meta will help Easter Seals Greater Houston determine whether wearable AI smart glasses improve accessibility for those with disabilities. The local nonprofit is one organization that received a share of $2 million that Meta allocated in late July.

"Meta is proud to select recipients, including the Easter Seals Greater Houston, based on demonstrated impact, scalability, and relevance to areas where hands-free technology can make the biggest difference," Meta executive Beth Murray said in a request for comment. "It was exciting to receive nearly 500 applications from organizations across the country, and now the real innovation begins here in Houston with the Easter Seals project to understand how different local communities can benefit from AI glasses."

Meta launched its AI Glasses Impact Grant program in January with the goal of delivering nearly $2 million in funds to organizations across the country to see how their Meta AI Glasses could improve people's lives. It selected over 30 recipients from more than 500 applicants.

Easter Seals is using the grant to help pay for its BridgingApps Program, "a community-centered pilot studying how three distinct populations — people with low vision, people with intellectual and developmental disabilities, and those with cognitive aging – can benefit from AI glasses," Meta says. Easter Seals is part of one of the oldest networks in America for disabilities, delivering disability support, veteran training, and other services. The Greater Houston branch was established in 1947.

Meta AI Glasses integrate AI personal assistance with wearable tech for a hands-free connective experience. While many people use their built-in cameras and social media access to create content, the Impact Grant promotes how the technology might assist people with disabilities as well as innovate in industrial and scientific fields.

Data storage and recall could aid people with memory loss, while interpretative AI facial recognition software may let neurodivergent and developmentally delayed people recognize social cues. The pilot program at Easter Seals will explore some of these possibilities.

Two other Texas organizations received grants. The University of North Texas will also explore disability assistance through Meta AI Glasses, in a school environment rather than in the general public space. Austin software company Embarcadero Technologies will use the glasses to build a remote training platform that can simultaneously mentor five junior workers at once.

---

This article originally appeared on CultureMap.com.

Houston startup lands $10M to power up electrician staffing platform

money moves

Houston-based Buildforce, which provides a tech-enabled staff platform geared toward electricians and electrical contractors, has raised a $10 million Series A round led by Houston’s Saepio Capital.

Other investors in the round include Blue Heron Capital, Revolution’s Rise of the Rest Seed Fund, S3 Ventures and Chicago Ventures.

Buildforce says the funding will help fuel its national expansion and further development of its technology.

The startup, founded in 2019, connects electricians with electrical contractors for commercial and industrial construction projects. Buildforce’s mobile app helps electricians find and carry out work, and a web app helps electrical contractors find and manage electricians.

“This financing is a major milestone in furthering our mission to help people dedicated to a career in the construction trades lead more secure and fulfilling lives,” co-founder and CEO Moody Heard said in a news release.

Buildforce focuses solely on the electrical trade within the construction sector.

Nick Graziano, principal at Blue Heron, says the shortage of electricians is intensifying as demand for electricians accelerates, driven by data center construction, infrastructure development and energy transition initiatives.

The U.S. Bureau of Labor Statistics estimates the U.S. will need to hire about 80,000 new electricians per year through 2032 to catch up with demand. According to the National Electrical Contractors Association, the U.S. is grappling with a current shortage of 50,000 electricians.

A 2026 economic report from asset manager BlackRock says the electrical trade is expected to be the single fastest-growing employment category in the U.S. labor market over the next 10 years.

“Buildforce is capitalizing on a clear opportunity in America’s generational infrastructure buildout. We believe their mission to use technology to improve lives in the construction space will allow them to make a positive long-term impact on a large and important labor market,” added Jaan Bains, managing partner at Saepio Capital.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME